RxDoctor Payments DataLook up a doctor →

Majid Mughal, MD

Interventional Cardiology · Okemos, MINPI 1992750723

Payments from drug & device makers

$438,634in general payments, 2019–2025

Across 578 payments — averaging $758.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$188K
  • Novartis$162K
  • Bayer$55K
  • AstraZeneca$23K
  • Medtronic$6K
  • Edwards Lifesciences$972
  • plus $4K from 23 others

What the payments were for

  • Consulting fees$1440%
  • Speaking & faculty fees$173,34288%
  • Travel & lodging$9,7065%
  • Food & beverage$12,8937%
  • Education$3410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$438,634 in reported general payments places this provider in the 85th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$166,091
Medicare patients
480
Services billed
1,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat158$2,140,567
Orenitram ErTreprostinil Diolamine52$1,224,174
OfevNintedanib Esylate65$855,070
OpsumitMacitentan50$629,731
Tyvaso DpiTreprostinil27$627,375
EliquisApixaban405$470,973
EntrestoSacubitril/Valsartan280$293,801
Trelegy ElliptaFluticasone/Umeclidin/Vilanter301$273,982
FarxigaDapagliflozin Propanediol157$162,657
ZemairaAlpha-1-Proteinase Inhibitor12$135,332
XareltoRivaroxaban80$113,787
JardianceEmpagliflozin77$99,125
Tadalafil59$40,678
Ambrisentan15$32,732
Repatha SureclickEvolocumab34$28,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$54,826$2,140,567158 claims
Boehringer IngelheimOfev, Jardiance, Spiriva Respimat, Stiolto Respimat$69$981,266179 claims
Actelion Pharmaceuticals US, Inc.Opsumit$158$629,73150 claims
PfizerEliquis$159$470,973405 claims
NovartisEntresto$162,174$293,801280 claims
AstraZenecaFarxiga, Symbicort$22,587$181,221215 claims
Johnson & JohnsonXarelto$362$113,78780 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Okemos

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →